UP1002 / UPPTHERA - LARVOL DELTA

Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance (AACR 2026) - "In the in vivo study, PLK1-PROTAC exerted significantly enhanced suppression of tumor growth compared with Oxaliplatin.CONCLUSIONSuppression of PLK1 expression led to a significant decrease in colorectal cancer cell function highlighting its essential role in sustaining tumor growth and metastatic functions. These findings suggest that PLK1 may serve as a potential therapeutic target for inhibiting colorectal cancer progression and overcoming chemoresistance."

Colorectal Cancer • Oncology • Solid Tumor • PLK1

An orally bioavailable, specific PLK1 bifunctional degrader for the treatment of small cell lung cancer and other cancers (AACR 2026) - "Moreover, combinations of UP1002 with multiple approved therapies showed synergistic or additive antitumor activity, highlighting its potential to enhance current treatment regimens. Together, these findings suggest that UP1002 has therapeutic potential in small-cell lung cancer and may extend its efficacy to additional cancer types."

Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CRBN • PLK1

N-Degron-Based PROTAC Targeting PLK1: A Potential Therapeutic Strategy for Cervical Cancer. (PubMed, Pharmaceutics) - "In vivo, NC1 suppressed tumor growth in a HeLa xenograft mouse model. This research highlights the potential of N-degron-based PROTACs targeting the PLK1 protein in cancer therapies, highlighting their potential in future cervical anticancer treatment strategies."

Journal • Cervical Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • PLK1